Menu
Recruiting NCT07660250

Vagus Nerve Stimulation for Myelopathy

No phase Interventional Degenerative Cervical Myelopathy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Vagus nerve stimulation (taVNS), Sham Stimulation.
Who it may be relevant to
Registry conditions: Degenerative Cervical Myelopathy. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Vagus Nerve Stimulation to Improve Post-operative Outcomes of Degenerative Cervical Myelopathy

Overview

The objective of this study is to generate preliminary data to establish the feasibility and effectiveness of transauricular vagus nerve stimulation (taVNS) to improve post-operative outcomes of moderate to severe degenerative cervical myelopathy (DCM)

Interventions

  • Device Vagus nerve stimulation (taVNS)
    Vagus nerve stimulation - clip is attached to ear
  • Device Sham Stimulation
    Clip will be attached to the ear, but no stimulation will be given.

Primary outcome measures

  • mJOA - Modified Japanese Orthopedics Association [Time frame: through study completion, an average of 1 year]
Secondary outcome measures (1)
  • Neck Disability Index (NDI) [Time frame: through study completion, an average of 1 year]

Eligibility criteria

Inclusion criteria

  • 18 years of age or older
  • Moderate or severe degenerative cervical myelopathy according to the mJOA
  • Decompression surgery planned

Exclusion criteria

  • • Pregnancy
  • Electrically active implants (e.g. pacemaker)
  • Known diagnosis of amyotrophic lateral sclerosis, multiple sclerosis, rheumatoid arthritis, concomitant thoracic and/or lumbar stenosis, spine tumor, HIV-related myelopathy
  • Ongoing cancer therapy
  • Ongoing use of immunomodulating or suppressive medication
  • Sustained bradycardia with a heartrate <50 beats per minute for > 5 minutes following admission.
  • Prior cervical spine surgery

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Washington University — St Louis

Identifiers

NCT: NCT07660250 · VNS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗